CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes.
Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本综述探讨了抗肿瘤T细胞应答背后的部分复杂机制,特别关注所选共刺激与抑制通路之间的平衡与交叉对话。肿瘤微环境(TME)既促进T细胞活化,也促进T细胞耗竭,这种双重作用受到局部抑制性免疫检查点(ICs)存在的影响,而癌细胞利用这些检查点来逃避免疫监视。IC阻断(ICB)疗法的最新进展已改变了癌症治疗。然而,只有一部分患者获得良好应答,这凸显了需要预测性生物标志物和联合疗法来克服ICB耐药。一个关键方面是TME的复杂性,其包含多种细胞类型,这些细胞或增强或抑制免疫应答。本综述强调了识别抑制性与共刺激分子之间最关键交叉对话的重要性,以便开发针对患者特异性分子和免疫谱量身定制的方法,从而最大化IC抑制剂的治疗疗效并改善临床结局。
This review explores some of the complex mechanisms underlying antitumor T-cell response, with a specific focus on the balance and cross-talk between selected co-stimulatory and inhibitory pathways. The tumor microenvironment (TME) fosters both T-cell activation and exhaustion, a dual role influenced by the local presence of inhibitory immune checkpoints (ICs), which are exploited by cancer cells to evade immune surveillance. Recent advancements in IC blockade (ICB) therapies have transformed cancer treatment.
However, only a fraction of patients respond favorably, highlighting the need for predictive biomarkers and combination therapies to overcome ICB resistance. A crucial aspect is represented by the complexity of the TME, which encompasses diverse cell types that either enhance or suppress immune responses.
This review underscores the importance of identifying the most critical cross-talk between inhibitory and co-stimulatory molecules for developing approaches tailored to patient-specific molecular and immune profiles to maximize the therapeutic efficacy of IC inhibitors and enhance clinical outcomes.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。